BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 11831066)

  • 1. [Therapy of Philadelphia chromosome positive acute lymphatic leukemia (Ph+ ALL) with an inhibitor of abl-tyrosine kinase (Glivec)].
    Ottmann OG; Wassmann B; Hoelzer D
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():16-21. PubMed ID: 11831066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
    Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
    Druker BJ; Sawyers CL; Kantarjian H; Resta DJ; Reese SF; Ford JM; Capdeville R; Talpaz M
    N Engl J Med; 2001 Apr; 344(14):1038-42. PubMed ID: 11287973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Results up to now of administration of STI-571 (Glivec) in recurrence after allogenic and autologous stem cell transplantation in chronic myeloid leukemia].
    Fischer T
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():22-7. PubMed ID: 11831068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Hoelzer D; Gökbuget N; Ottmann OG
    Semin Hematol; 2002 Oct; 39(4 Suppl 3):32-7. PubMed ID: 12447850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back.
    von Bubnoff N; Peschel C; Duyster J
    Leukemia; 2003 May; 17(5):829-38. PubMed ID: 12750693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia: current status and evolving concepts.
    Ottmann OG; Wassmann B
    Best Pract Res Clin Haematol; 2002 Dec; 15(4):757-69. PubMed ID: 12617875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
    Hochhaus A; Kreil S; Corbin AS; La Rosée P; Müller MC; Lahaye T; Hanfstein B; Schoch C; Cross NC; Berger U; Gschaidmeier H; Druker BJ; Hehlmann R
    Leukemia; 2002 Nov; 16(11):2190-6. PubMed ID: 12399961
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.
    La Rosée P; O'Dwyer ME; Druker BJ
    Leukemia; 2002 Jul; 16(7):1213-9. PubMed ID: 12094245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia.
    Gruber F; Mustjoki S; Porkka K
    Br J Haematol; 2009 Jun; 145(5):581-97. PubMed ID: 19388927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new drug in the therapy of chronic myeloid leukemia: ST1571].
    Salesi N; Bossone G; Della Longa G; Di Cocco B
    Minerva Med; 2003 Apr; 94(2):71-6. PubMed ID: 12858155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
    Pfeifer H; Lange T; Wystub S; Wassmann B; Maier J; Binckebanck A; Giagounidis A; Stelljes M; Schmalzing M; Dührsen U; Wunderle L; Serve H; Brück P; Schmidt A; Hoelzer D; Ottmann OG
    Leukemia; 2012 Jul; 26(7):1475-81. PubMed ID: 22230800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
    Chien JH; Tang JL; Chen RL; Li CC; Lee CP
    Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [STI571 (Glivec)--a new drug for the treatment of chronic myeloid leukemia].
    Hasselbalch HC
    Ugeskr Laeger; 2002 May; 164(22):2914-7. PubMed ID: 12082821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of inoperable gastrointestinal stromal tumor (GIST) with Imatinib (Glivec, Gleevec).
    Joensuu H
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():28-30. PubMed ID: 11831069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment approaches for chronic myelogenous leukemia.
    Druker BJ
    Cancer J; 2001; 7 Suppl 1():S14-8. PubMed ID: 11504279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signal transduction inhibitors (STI571): molecularly targeted therapy.
    Corujo Y; Cáceres W
    P R Health Sci J; 2002 Sep; 21(3):203-5. PubMed ID: 12243110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.